
|Articles|May 21, 2019
Xcenda Announces Acquisition of Dymaxium
Advertisement
Xcenda, a part of AmerisourceBergen, has acquired Dymaxium, a market access partner specializing in the exchange of evidence and information between payers and life science companies.
This acquisition will further simplify and streamline the necessary communication of clinical evidence and health economic information between manufacturers and population health decision makers.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
GSK Enters Multi-Year Collaboration with Helix to Develop Precision Medications
2
Pharmaceutical Executive Daily: Amgen Acquires Dark Blue Therapeutics for $840 Million
3
Novo Nordisk’s Wegovy Pill Becomes First Oral GLP-1 Available in U.S.
4
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
5




